Glaukos (NYSE: GKOS) COO sells shares after exercising options

Rhea-AI Filing Summary

Glaukos Corporation’s President and COO, Joseph E. Gilliam, reported option exercises and related share sales. On January 22, 2026, he exercised stock options for 10,498 shares of common stock at an exercise price of $55.18 per share, from options originally granted on March 24, 2022 that were tied to multi-year performance goals and operational targets.

On the same date, he sold blocks of Glaukos common stock totaling 2,406, 3,100, 1,798 and 3,194 shares at weighted average prices of $126.10, $127.03, $128.07 and $129.28, respectively. These transactions, as well as the option exercises, were carried out under a Rule 10b5-1 trading plan adopted on June 11, 2025. After these transactions, Gilliam beneficially owned 92,366 shares of common stock, which includes 62,605 restricted stock units that have not yet vested or been delivered.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gilliam Joseph E

(Last) (First) (Middle)

C/O GLAUKOS CORPORATION

ONE GLAUKOS WAY

(Street)

ALISO VIEJO CA 92656

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GLAUKOS Corp [ GKOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT & COO

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/22/2026		M		10,498	A	$55.18	102,864(1)	D
Common Stock	01/22/2026		S(2)		2,406	D	$126.1(3)	100,458(1)	D
Common Stock	01/22/2026		S(2)		3,100	D	$127.03(4)	97,358(1)	D
Common Stock	01/22/2026		S(2)		1,798	D	$128.07(5)	95,560(1)	D
Common Stock	01/22/2026		S(2)		3,194	D	$129.28(6)	92,366(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$55.18	01/22/2026		M(7)			7,398	(8)	03/24/2032	Common Stock	7,398	$55.18	55,013	D
Stock Option (Right to Buy)	$55.18	01/22/2026		M(7)			3,100	(9)	03/24/2032	Common Stock	3,100	$55.18	30,713	D

Explanation of Responses:

1. Includes 62,605 restricted stock units that have not yet vested or been delivered to the Reporting Person.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.

3. This transaction was executed in multiple trades at prices ranging from $125.56 to $126.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $126.62 to $127.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $127.83 to $128.77. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. This transaction was executed in multiple trades at prices ranging from $128.98 to $129.81. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

7. The option exercises reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.

8. Represents a portion of an option to purchase shares of common stock previously granted by the Issuer on March 24, 2022, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period.

9. Represents a portion of an option to purchase shares of common stock previously granted by the Issuer to the Reporting Person on March 24, 2022 in connection with his promotion to President and Chief Operating Officer, the vesting of which was subject to the Issuer's achievement of certain multi-year performance goals.

	Diana Scherer, Attorney-in-Fact	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Glaukos (GKOS) report for its President & COO?

The President & COO, Joseph E. Gilliam, reported exercising stock options for 10,498 shares of Glaukos common stock at an exercise price of $55.18 per share and selling several blocks of common stock on January 22, 2026.

At what prices did the Glaukos (GKOS) President & COO sell shares?

On January 22, 2026, Joseph E. Gilliam sold Glaukos common stock in multiple trades: 2,406 shares at $126.10, 3,100 shares at $127.03, 1,798 shares at $128.07, and 3,194 shares at $129.28, with each price reported as a weighted average for multiple executions.

Was the Glaukos (GKOS) insider trading activity under a 10b5-1 plan?

Yes. The filing states that both the sales and the option exercises reported were effected pursuant to a Rule 10b5-1 trading plan adopted by Joseph E. Gilliam on June 11, 2025.

How many Glaukos (GKOS) shares does the President & COO own after these transactions?

Following the reported transactions, Joseph E. Gilliam beneficially owned 92,366 shares of Glaukos common stock, which the filing notes includes 62,605 restricted stock units that have not yet vested or been delivered.

What stock options did the Glaukos (GKOS) President & COO exercise?

He exercised portions of two stock options granted on March 24, 2022. One covered 7,398 shares and the other 3,100 shares, both with an exercise price of $55.18 per share, and their vesting depended on Glaukos achieving multi-year performance and operational targets.

Is Joseph E. Gilliam a director or major shareholder of Glaukos (GKOS)?

According to the filing, Joseph E. Gilliam is reported as an officer of Glaukos, serving as President & Chief Operating Officer, and is not indicated as a director or a 10% owner.